Search Results - "van der Zwet, Konrad"

Bleeding control improves after switching to emicizumab: Real-world experience of 177 children in the PedNet registry by van der Zwet, Konrad, de Kovel, Marloes, Motwani, Jayashree, van Geet, Chris, Nolan, Beatrice, Glosli, Heidi, Escuriola Ettingshausen, Carmen, Königs, Christoph, Kenet, Gili, Fischer, Kathelijn

“…Despite the rapid uptake of emicizumab in the paediatric haemophilia A (HA) population, real-world data on the safety and efficacy is limited. To report on…”
Get full text

DosEmi study protocol: a phase IV, multicentre, open-label, crossover study to evaluate non-inferiority of pharmacokinetic-guided reduced dosing compared with conventional dosing of emicizumab in people with haemophilia A by Donners, Anouk, van der Zwet, Konrad, Egberts, Antoine C G, Fijnvandraat, Karin, Mathôt, Ron, Kruis, Ilmar, Cnossen, Marjon H, Schutgens, Roger, Urbanus, Rolf T, Fischer, Kathelijn

“…IntroductionEmicizumab effectively prevents bleeding in people with haemophilia A (PwHA), but is a burden for national healthcare budgets and consequently may…”
Get full text

Longitudinal assessment of anti-PGL-I serology in contacts of leprosy patients in Bangladesh by Richardus, Renate A, van der Zwet, Konrad, van Hooij, Anouk, Wilson, Louis, Oskam, Linda, Faber, Roel, van den Eeden, Susan J F, Pahan, David, Alam, Khorshed, Richardus, Jan Hendrik, Geluk, Annemieke

“…Despite elimination efforts, the number of Mycobacterium leprae (M. leprae) infected individuals who develop leprosy, is still substantial. Solid evidence…”
Get full text

The efficacy of the entire-vial dosing of emicizumab: Real-world evidence on plasma concentrations, bleeds, and drug waste by Donners, Anouk A.M.T., van der Zwet, Konrad, Rademaker, Carin M.A., Egberts, Toine C.G., Schutgens, Roger E.G., Fischer, Kathelijn

“…Prophylaxis with emicizumab provides effective bleeding protection in persons with hemophilia A (PwHA) but pressures healthcare budgets. The body…”
Get full text

Navigating the challenges: a case report on managing a complicated postpartum course in type 3 von Willebrand disease with alloantibodies by van der Zwet, Konrad, van Galen, Karin P.M., Evers, Annemiek C.C., Fischer, Kathelijn, Schutgens, Roger E.G., van Vulpen, Lize F.D.

“…Von Willebrand disease (VWD) type 3 is characterized by a complete deficiency of von Willebrand factor (VWF), resulting in a severe bleeding phenotype…”
Get full text

The Emicizumab Switch: Real-World Data of 251 Pediatric Patients from the Pednet Registry by Van Der Zwet, Konrad, de Kovel, Marloes, Motwani, Jayashree, Van Geet, Christel, Nolan, Beatrice, Glosli, Heidi, Kenet, Gili, Fischer, Kathelijn

Get full text

Navigating the challenges: a case report on managing a complicated postpartum course in type 3 von Willebrand disease with alloantibodies by van der Zwet, Konrad, van Galen, Karin P M, Evers, Annemiek C C, Fischer, Kathelijn, Schutgens, Roger E G, van Vulpen, Lize F D

“…BackgroundVon Willebrand disease (VWD) type 3 is characterized by a complete deficiency of von Willebrand factor (VWF), resulting in a severe bleeding…”
Get full text